

Wojciech Rzechorzek¹, Michalina Szańkowska¹, Benedykt Szczepankiewicz², Agata Cyran-Chlebicka², Aleksandra Safianowska³

¹Student Interest Group "Alveolus", Department of Internal Diseases, Pulmonology, and Allergology, Medical University of Warsaw, Poland

Tutor: Prof. J. Domagała-Kulawik, MD, PhD

²Chair and Department of Pathomorphology, Medical University of Warsaw, Poland

Head: Prof. B. Górnicka, MD, PhD

³Department of Internal Diseases, Pulmonology, and Allergology, Medical University of Warsaw, Poland

Head: Prof. R. Chazan, MD, PhD

Detecting *Mycobacterium tuberculosis* complex DNA, based on post-mortem examination of hilar lymph nodes with real-time PCR: initial study

Wykrywanie DNA *Mycobacterium tuberculosis* complex, na podstawie badania *post mortem* węzłów chłonnych węzkowych, metodą real-time PCR — doniesienie wstępne

Study supported by Medical University of Warsaw, Poland, Grant N° 1wu/nm1/11

Abstract

Introduction: According to the WHO, almost a third of the world population are thought to be infected with *Mycobacterium tuberculosis*. Some studies of the prevalence of latent tuberculosis infection (LTBI) have already been performed in Poland, showing that almost a quarter of the Mazovia population could be infected. It also indicated a higher prevalence of LTBI among seniors. Those studies were based on indirect diagnostic methods.

Material and methods: We randomly collected hilar lymph nodes from decedents aged 40 years and older during post-mortem examination. We excluded patients with previous confirmed tuberculosis. In addition, an autopsy was performed in all patients. Finally, we used real-time PCR Xpert MTB/RIF (Cepheid, USA) for the specific capture of mycobacterial DNA.

Results: Twenty-two of 23 patients had a negative result of the real-time PCR examination and no signs of caseous necrosis in hilar lymph nodes. We found the only positive sample in a patient with histopathological signs of tuberculosis (the presence of caseous necrosis in the specimens obtained from lymph nodes and lung). Due to the change of cartridges from version G3 to G4, further reactions were inhibited and no more post-mortem samples were tested.

Conclusions: Real-time PCR Xpert MTB/RIF was capable of detecting *M. tuberculosis* complex DNA in a patient with tuberculosis recognised on autopsy. In the remaining patients, no *M. tuberculosis* complex DNA was found, in accordance with negative results of histological examination. Since the technology of cartridges has changed, it is no longer possible to use real-time PCR Xpert MTB/RIF (Cepheid USA) on post-mortem material.

Key words: *M. tuberculosis* complex DNA, latent tuberculosis infection, real-time PCR, Xpert MTB/RIF

Pneumonol. Alergol. Pol. 2014; 82: 430–435

Address for correspondence: W. Rzechorzek, Student Interest Group "Alveolus", Department of Internal Diseases, Pulmonology, and Allergology, ul. Banacha 1a, 02–097 Warsaw, Poland, Tel.: +48 605 160 106, e-mail: wrzechorzek@gmail.com

DOI: 10.5603/PiAP.2014.0056

Praca wpłynęła do Redakcji: 22.07.2013 r.

Copyright © 2014 PTChP

ISSN 0867–7077

Streszczenie:

Wstęp: Zgodnie z danymi Światowej Organizacji Zdrowia, uważa się, że prawie 1/3 światowej populacji jest zakażona prątkiem gruźlicy. Wyniki badań prowadzonych przy użyciu pośrednich metod diagnostycznych nad rozpowszechnieniem utajonego zakażenia prątkiem gruźlicy w Polsce wykazały, że nawet 1/4 populacji Mazowska może być zakażona, z przewagą u osób starszych.

Materiał i metody: Podczas badania *post-mortem* pobierano w sposób losowy węzły chłonne węłkowe od zmarłych w wieku 40 lat i powyżej. Na podstawie danych z historii chorób wykluczono pacjentów leczonych z powodu gruźlicy w przeszłości. U wszystkich chorych przeprowadzono badanie sekcyjne. Następnie wykonywano badanie real-time PCR, Xpert MTB/RIF, Cepheid, USA w celu wykrycia DNA *Mycobacterium tuberculosis* complex.

Wyniki: U 22 z 23 pacjentów wynik reakcji real-time PCR był negatywny, a w preparatach węzłów chłonnych nie stwierdzono ziarniny serowaciejącej. W jednym przypadku badanie real-time PCR było dodatnie. Dotyczyło to chorego, u którego stwierdzono obecność ziarniny serowaciejącej zarówno w preparatach z węzłów chłonnych, jak i pobranych z nacieku płucnego. Po zmianie kartridży z wersji G3 na G4 w real-time PCR, Xpert MTB/RIF kolejne reakcje były zahamowane i nie testowano większej liczby próbek.

Wnioski: Badanie metodą real-time PCR, Xpert MTB/RIF wykazało obecność *M. tuberculosis* complex DNA u chorego z pośmiertnie stwierdzoną gruźlicą płuc i ww. chłonnych. U pozostałych chorych nie wykryto obecności DNA *M. tuberculosis* complex w tkankach, co pozostawało w zgodzie z negatywnym wynikiem badania histologicznego. Po zmianie technologii badania real-time PCR, Xpert MTB/RIF zawodzi przy badaniu próbek z materiału uzyskanego pośmiertnie.

Słowa kluczowe: gruźlica utajona, real-time PCR, Xpert MTB/RIF

Pneumonol. Alergol. Pol. 2014; 82: 430–435

Introduction

According to the WHO, almost a third of the world population could be infected with *M. tuberculosis* [1]. In countries endemic for TB, the greatest number of new cases of tuberculosis is the result of recent contact with an infectious case of tuberculosis, whereas in developed countries with low prevalence of pulmonary TB, new cases of TB appear to be due to the reactivation of LTBI [2].

Latent tuberculosis infection (LTBI) is a condition in which *M. tuberculosis* is suppressed by the immune response of the host. Although tubercle bacillus does not replicate, it remains in old lesions. There are two models describing the possible location of the bacilli during the latency. In the “focal” model, *M. tuberculosis* remains in old granulomatous lesions and draining regional lymph nodes, which correspond to the Gohn complex. According to the “diffuse” model, bacilli are distributed all over the lungs and other tissues [3]. A patient with LTBI does not transmit the disease, in contrast to the active form of tuberculosis (TB), in which the host infects up to 10–30 people per year [4].

The incidence of tuberculosis per 100,000 population in Europe is 50 in Lithuania and Estonia and 10–20 in the United Kingdom, France, and Germany. In Poland after World War II the incidence of tuberculosis was very high, reaching over 300 per 100,000 population, and remained high until the 1960s, when it started to decrease

gradually partly as a result of previous introduction of successful anti-tuberculous treatment [4]. Afterwards, the permanently declining incidence rate of tuberculosis led to similar levels to those seen in developed countries, i.e. 19.6 per 100,000 population in 2012 [5].

The incidence notification rates of TB differ depending on the age group. Among seniors aged 45–64 and 65+ the incidence is much higher than in other age groups, reaching 32.1 and 34.8 per 100,000 population, respectively [5].

Likewise, the prevalence of LTBI according to the results of Kuś et al., based on interferon gamma release assay (IGRA), was higher among older people [6]. In this study it was shown that almost a quarter of the Mazovian population could be infected [6].

Taking into consideration the high prevalence of tuberculosis in Poland in the past and the positive correlation between IGRA results and age, it can be presumed that the incidence of tuberculosis among seniors nowadays could be the result of reactivation of latent infection.

Factors connected with the immunological status of the patient can facilitate the change from dormant bacilli state to clinical manifestation of tuberculosis. These include, among others, immunodeficiency due to immunosuppressive drugs, including anti-TNF therapy, or diseases such as diabetes, cancer, or HIV infection [7, 8].

People with latent infection have neither symptoms nor radiographic evidence of active TB. In the absence of bacilli in sputum or any clinical

probe, LTBI cannot be detected with classical microbiological methods, neither bacterioscopy nor culture. Consequently, there is no gold-standard test to determine LTBI. Current tools to diagnose LTBI include physical examination and history of TB contact. Tuberculin skin test (TST) and IGRA are indirect methods to investigate LTBI, based on the fact that after contact with bacilli, the lymphocytes of the human host are sensitised to *M. tuberculosis* antigens, and the immunological memory persists. According to the indirect character of the tests, many false positive and false negative results can occur [9]. However, these tests cannot inform us with certainty about the current presence of tubercle bacilli and do not distinguish the past from present infection, regardless of whether or not it is active. Consequently, the exact prevalence of LTBI is not known [10, 11].

Taking into consideration all of the epidemiological and pathophysiological data, we decided to establish whether it is possible to detect *M. tuberculosis* complex DNA by direct method, real-time PCR, in decedents aged 40 years and older, who were free from clinically recognisable tuberculosis in the past.

Material and methods

In the first step of our study we randomly collected hilar lymph nodes from decedents aged 40 years and older during post-mortem examinations (Fig. 1). Autopsies were performed on patients from the Central Clinical Hospital in Warsaw. The material was collected by anatomopathologists, placed into a physiological salt solution, and frozen at -20°C .



Figure 1. Hilar lymph nodes

Author: Benedykt Szczepankiewicz, MD, PhD Chair and Department of Pathomorphology (7 Pawińskiego str., 02–106 Warsaw, Poland)

In the second step, we analysed medical case histories, chest X-ray examinations, and/or computer tomography (CT) scans of decedents whose lymph nodes were collected. We excluded the material from patients with proven TB in the past. We also excluded the material from decedents with signs of cavitation suggesting active TB. Autopsy was performed in all of the patients.

Finally, to permit the specific capture of mycobacterial DNA, we used real-time PCR, Xpert MTB/RIF, version G3 (Cepheid, USA) [12]. We performed tests as an off label use on tissue specimens, previously validated by our laboratory. We did not use any methods to purify the material from tissue inhibitors. We used the same procedure as in sputum examination, as described in the manufacturer's guidelines [13].

Results

We examined 23 patients within the age range of 40–97 years (average 70), 8 (35%) of whom were men. In all of the medical data, we found no signs of active TB. Eight of 23 patients had CT scans of the chest. Focal consolidations either in upper lobes or in superior parts of lower lobes and lymphadenopathy were present in four patients, and isolated lymphadenopathy in one case. No signs of cavitation were present in CT scans. Other results of CT scans are presented in Table 1.

In the examined group, 22 out of 23 patients had a negative result of the real-time PCR and histopathological signs of tuberculosis were not found. The histological results and clinical diagnosis of patients are summarised in Table 1.

The only positive sample was found in a 64-year-old patient with signs of tuberculosis. The autopsy revealed a $4 \times 4 \times 3$ cm white/yellow amorphous lesion consistent with the foci of caseous necrosis, localised in the upper lobe of the right lung. Hilar lymph nodes were enlarged (2 cm in diameter). Microscopic necrosis and granulomatous reaction with multinucleate giant cells were present. The patient was referred to the neurosurgical department because of coma and severe subarachnoid haemorrhage. In addition, he suffered from diabetes and HCV infection. Blood tests, taken before death, revealed CRP — less than 5 mg/L [< 10 mg/L] and WBC of $24.15 \times 1000/\text{mm}^3$ [$4\text{--}10 \times 1000/\text{mm}^3$]. After four days of hospitalisation, the patient underwent brain-stem death. There was not enough data in case history or in X-ray examination to establish if the patient was symptomatic.

Table 1. Individual patients' results

Gender	Age	real-time PCR result P-positive N-negative	Clinical diagnosis of tuberculosis A-absent P-present	Thorax CT scan pathologies	Autopsy findings
Male	85	N	A	Bilateral massive consolidations; Enlarged para-aortic lymph nodes (l.n.)	Oedema/lung congestion
Male	62	N	A	Bilateral interstitial changes, glass-like infiltrates; Enlarged right hilar and mediastinal l.n.; Bilateral pleural effusions	Oedema/lung congestion
Male	85	N	A	Perihilar inflammatory consolidation, left lung; Enlarged left, inferior, paratracheal l.n.; Nodules, left lung, interlobar fissure (<8mm); Bilateral pleural effusions	Oedema/lung congestion
Male	60	N	A	Bilateral enlarged axillary, mediastinal and cavital l. n.; Nodules, right lung, upper lobe (4 mm), medial lobe (3 mm) and lower lobe (6 mm); Focal fibrosis- left lung; Pleural effusions, left lung	Enlarged mediastinal lymph nodes
Female	63	N	A	Enlarged bilateral axillary, mediastinal and right cavital l.n.; Bronchial consolidations, right lung, upper and lower lobes; Consolidations, left lung medial and lower lobes	Inflammatory changes in both lungs
Male	75	N	A		Congestion/atelectasis
Male	64	P	P		4 × 4 × 3-cm white/yellow amorphous lesion consistent with the foci of caseous necrosis localized in upper lobe of the right lung, enlarged hilar lymph nodes (2 cm in diameter). Microscopically necrosis and granulomatous reaction with multinucleate giant cells
Male	83	N	A		Oedema/lung congestion
Female	58	N	A		Oedema/lung congestion
Female	97	N	A	Nodules, bilateral, partially calcified (small)	Massive bilateral pleural effusion
Female	80	N	A		Oedema/lung congestion
Female	70	N	A	Nodules left lung 9 seg. (4 and 5 mm) Bilateral basal atelectasis; Bilateral pleural effusions	Inflammatory changes in both lungs
Female	61	N	A		No changes
Male	63	N	A		Purulent bronchitis, emphysema, focal siderophages, congestion, focal oedema,
Male	64	N	A		Oedema/lung congestion
Male	54	N	A		Oedema/congestion, small focal fibrosis in right lung
Male	76	N	A		Congestion/atelectasis
Male	40	N	A		Oedema/congestion, purulent bronchitis
Female	58	N	A		Lung congestion
Female	89	N	A	Enlarged mediastinal l.n.; Focal change, right lung, 10 th segment (15*20 mm)	Bronchopneumonia
Female	79	N	A		Lung tumour enlarged right hilar lymph nodes
Male	77	N	A		Atelectasis
Male	57	N	A	Enlarged axillar, mediastinal and cavital l.n.; Bilateral glass-like infiltrates (possible CMV aetiology); Bilateral basal subpleural nodules	Small nodule in the lower lobe of the right lung, oedema/congestion, enlarged hilar lymph nodes

Discussion

In spite of the vast knowledge of *M. tuberculosis* and numerous new methods to detect bacilli, there are still unanswered questions in the field of examinations. It is impossible to do the following: estimate the number of people that are infected in a latent manner; fully eliminate bacteria after the primary infection; or predict the risk of progression to the disease in patients with persistent anti-mycobacterial immune responses [10].

The percentage of people exposed to tuberculosis, who develop infection varies from 30 to 95%, according to different specialists [1, 14]. The majority (90%) of people exposed to tuberculosis develop localized infection, which in up to 90% of cases leads to LTBI [15]. Reactivation of the infection is possible in 5-10% of those cases, even many years after the primary infection [16, 17].

In post-primary *M. tuberculosis* infection, radiological changes include focal consolidations in upper lobes and superior parts of lower lobes, rarely accompanied by lymphadenopathy. Cavitation is a sign of active disease, with high infectivity and higher risk of complications [18].

In the present study, thorax CT scans were obtained in eight patients. Although lung pathology was present in all of them, taking into consideration the negative histopathological examination and the lack of previous diagnosis of tuberculosis, none of them had signs consistent with active TB.

Most LTBI studies are based on indirect methods of investigation, including TST and IGRA [3, 19]. The aim of our study was to detect *M. tuberculosis* complex DNA using real-time PCR, Xpert MTB/RIF (Cepheid, USA) in material from patients with low probability of active tuberculosis. Although the method is designed to detect *M. tuberculosis* complex in sputum and BAL, it is also used with success to test the material from solid tissues, including extra-pulmonary locations [12, 20]. In a systematic review and meta-analysis, Denkinger et al. noted Xpert MTB/RIF pooled sensitivity of 83.1% (95% CI 71.4–90.7%) and pooled specificity of 93.6% (95% CI 87.9–96.8%) against culture in material from lymph node tissues or aspirates [21]. This study included results from our laboratory.

In four samples from mediastinal lymph nodes examined with real-time PCR during routine diagnostic procedure, two were positive and none of the reactions were inhibited [13]. The same procedure was performed by our group in 14 different samples, with two positive results [unpublished data]. Tortoli et al. reported that

in reference to the culture and clinical diagnosis of TB, sensitivity and specificity of Xpert MTB/RIF reaches 81.3% and 99.8%, respectively [22]. According to some authors, there have been successful attempts to detect DNA of *M. tuberculosis* complex in paraffin-embedded blocks already performed using PCR amplification methods [23, 24].

We used Xpert MTB/RIF, which is based on the Automated Nucleic Acid Amplification Test and is capable of detecting even small amounts of DNA of *M. tuberculosis* complex. Furthermore, *rpoB* detected with real-time PCR is a very conservative gene present among *M. tuberculosis* complex. Markers used in real-time PCR detect mutations in this gene specific for *M. tuberculosis* complex, including ones responsible for resistance to rifampicin. Research on tuberculosis shows superiority (greater specificity and sensitivity) of real-time PCR over other methods, such as acid-fast bacilli culture or nested PCR [11]. The advantage of the test is the integrated internal control to monitor the validity of the assay, to exclude negative result due to potential polymerase inhibitors present in tissues [25]. In the presented study, all reactions were valid according to performed internal controls.

A drawback of the study with post-mortem material is that IGRA or TST are impossible. Therefore, we had only incomplete medical documentation, CT scans, and histopathological examination to evaluate clinical data and determine potential infections in patients.

Taking into consideration the high sensitivity and specificity of real-time PCR, the epidemiology of TB and LTBI, along with the age of the patients in our group, the chance of obtaining positive results seemed high. In our study we collected hilar lymph nodes, relying on the “focal” model of tuberculosis. However, the “diffuse” model of tuberculosis is a valid alternative, so, to some extent, the distribution of *M. tuberculosis* bacilli could be the cause of negative results. Because of financial limitations, it was not possible to examine whole lungs and all of the mediastinal lymph nodes, possible locations of *M. tuberculosis* according to the diffuse model.

In the only positive Xpert MTB/RIF case, histopathological examination confirmed the presence of caseous necrosis in lungs and regional lymph nodes, which, combined with a positive result of Xpert MTB/RIF, allowed us to recognise active tuberculosis according to the guidelines of the Polish Society of Lung Diseases [26].

Although initially we wanted to perform 40 reactions, the technology of cartridges in real-time

PCR Xpert MTB/RIF (Cepheid, USA) has changed. The version (G3) that we were using was replaced by a new version (G4). The technological details of the change between versions of the cartridges were reserved by the manufacturer. We performed three reactions, which were inhibited, so we decided to interrupt our study. Therefore, no more samples were tested.

Conclusions

Real-time PCR, Xpert MTB/RIF was capable of detecting *M. tuberculosis* DNA in a patient with tuberculosis recognised on autopsy.

In the remaining patients, no *M. tuberculosis* complex DNA was found, which was consistent with the negative results of histological examination.

Since the technology of cartridges has changed, it is no longer possible to use Xpert MTB/RIF on post-mortem material.

Conflict of interest

The authors declare no conflict of interest.

References:

- World Health Organisation. Tuberculosis: fact sheets. <http://www.who.int/mediacentre/factsheets/fs104/en/index.html>; 02.07.2014.
- Amanatidou V., Syridou G., Mavrikou M., Tsolia M.N. Latent tuberculosis infection in children: diagnostic approaches. *Eur. J. Clin. Microbiol. Infect. Dis.* 2012; 31: 1285–1294.
- Parrish N.M., Dick D.J., Bishai W.R. Mechanisms of latency in *Mycobacterium tuberculosis*. *Trends Microbiol.* 1998; 6: 107–112.
- Kwiatkowska S. Gruźlica w Polsce i na świecie. *Alergia* 2008; 2: 41–44.
- Korzeniewska-Koseła M. ed. Tuberculosis and lung diseases in Poland in 2012. Instytut Gruźlicy i Chorób Płuc, Warszawa 2013; 29.
- Kus, J., Demkow U., Lewandowska K. et al. Prevalence of latent infection with *Mycobacterium tuberculosis* in Mazovia Region using interferon gamma release assay after stimulation with specific antigens ESAT-6 and CFP-10. *Pneumonol. Alergol. Pol.* 2011; 79: 407–418.
- Mack U., Migliori G.B., Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to *M. tuberculosis*? A TBNET consensus statement. *Eur. Respir. J.* 2009; 33: 956–973.
- Kapoor N., Pawar S., Sirakova T.D. et al. Human granuloma in vitro model, for TB dormancy and resuscitation. *PLoS One* 2013; 8: e53657.
- Abdallhamid B., Hinrichs S.H., Garrett J.L. et al. Utilization of the QuantiFERON-TB Gold Test in a two — step process with the Tuberculin Skin Test to evaluate health care workers for latent tuberculosis. *J. Clin. Microbiol.* 2010; 48: 2955–2956.
- Lee H. S., Park K.U., Park J.O. et al. Rapid, sensitive, and specific detection of *Mycobacterium tuberculosis* complex by real-time PCR on paraffin-embedded human tissues. *J. Mol. Diagn.* 2011; 13: 390–394.
- Norbis L., Miotto P., Alagna R., Cirillo D.M. Tuberculosis: lights and shadows in the current diagnostic landscape. *New Microbiol.* 2013; 36: 111–120.
- Helb D., Jones M., Story E. et al. Rapid detection of *Mycobacterium tuberculosis* and rifampin resistance by use of on-demand, near-patient technology. *J. Clin. Microbiol.* 2010; 48: 229–237.
- Safianowska A., Walkiewicz R., Nejman-Gryz P., Grubek-Jaworska H. The use of selected commercial molecular assays for microbiological diagnosis of tuberculosis. *Pneumonol. Alergol. Pol.* 2012; 80: 6–12.
- Tortoli E. Diagnosi immunologia della tubercolosi. <http://www.mycobactoscana.it/Testi/Interferon.pps>; 02.07.2014.
- Ahmad S. Pathogenesis, immunology, and diagnosis of latent *Mycobacterium tuberculosis* infection. *Clin. Dev. Immunol.* 2011; 2011: 814943.
- Gupta D., Agarwal R., Aggarwal A.N., Jindal S.K. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. *Eur. Respir. J.* 2007; 30: 508–516.
- Lillebaek T., Dirksen A., Baess I. et al. Molecular evidence of endogenous reactivation of *Mycobacterium tuberculosis* after 33 years of latent infection. *J. Infect. Dis.* 2002; 185: 401–404.
- McAdams H.P., Erasmus J., Winter J.A. Radiologic manifestations of pulmonary tuberculosis. *Radiol. Clin. North Am.* 1995; 33: 655–678.
- Horsburgh C.R. Jr., Rubin E.J. Clinical practice. Latent tuberculosis infection in the United States. *N. Engl. J. Med.* 2011; 364: 1441–1448.
- Boehme C.C., Nabeta P., Hillemann D. et al. Rapid molecular detection of tuberculosis and rifampin resistance. *N. Engl. J. Med.* 2011; 363: 1005–1015.
- Denkinger C., Schumacher S.G., Boehme C.C. et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur. Respir. J.* 2014 Apr 2 [Epub ahead of print as doi: 10.1183/09031936.00007814].
- Tortoli E., Russo C., Piersimoni C. et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. *Eur. Respir. J.* 2012; 40: 442–447.
- Ishige I., Usui Y., Takemura T., Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. *Lancet* 1999; 354: 120–123.
- Zhou Y., Li H.P., Li Q.H. et al. Differentiation of sarcoidosis from tuberculosis using real-time PCR assay for the detection and quantification of *Mycobacterium tuberculosis*. *Sarcoidosis Vasc. Diffuse Lung. Dis.* 2008; 25: 93–99.
- Chawla K., Gupta S., Mukhopadhyay Ch., Rao P.S., Bhat S.S. PCR for *M. tuberculosis* in tissues samples. *J. Infect. Dev. Countr.* 2009; 3: 83–87.
- Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania, leczenia i zapobiegania gruźlicy u dorosłych i dzieci. *Pneumonol. Alergol. Pol.* 2013; 81: 323–379.

